vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and VersaBank (VBNK). Click either name above to swap in a different company.
AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $26.7M, roughly 1.7× VersaBank). VersaBank runs the higher net margin — 30.3% vs -19.9%, a 50.3% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 31.2%). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 16.6%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
VersaBank is a Canada-based digital-first financial institution offering commercial lending, high-interest deposit accounts and customized financial services for SMEs, retail clients and institutional partners across North America. It operates no physical branches, using secure digital infrastructure to deliver efficient, cost-effective banking experiences.
ABCL vs VBNK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $26.7M |
| Net Profit | $-8.9M | $8.1M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | — |
| Net Margin | -19.9% | 30.3% |
| Revenue YoY | 788.4% | 31.2% |
| Net Profit YoY | 73.9% | 35.9% |
| EPS (diluted) | $-0.03 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.7M | ||
| Q4 25 | $44.9M | — | ||
| Q3 25 | $9.0M | $23.1M | ||
| Q2 25 | $17.1M | $22.0M | ||
| Q1 25 | $4.2M | $20.3M | ||
| Q4 24 | $5.0M | — | ||
| Q3 24 | $6.5M | $19.7M | ||
| Q2 24 | $7.3M | $20.8M |
| Q1 26 | — | $8.1M | ||
| Q4 25 | $-8.9M | — | ||
| Q3 25 | $-57.1M | $4.8M | ||
| Q2 25 | $-34.7M | $6.2M | ||
| Q1 25 | $-45.6M | $5.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-51.1M | $7.1M | ||
| Q2 24 | $-36.9M | $8.6M |
| Q1 26 | — | — | ||
| Q4 25 | -63.7% | — | ||
| Q3 25 | -851.8% | — | ||
| Q2 25 | -290.2% | — | ||
| Q1 25 | -1479.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1439.4% | — | ||
| Q2 24 | -1276.2% | — |
| Q1 26 | — | 30.3% | ||
| Q4 25 | -19.9% | — | ||
| Q3 25 | -637.8% | 20.8% | ||
| Q2 25 | -203.3% | 28.3% | ||
| Q1 25 | -1077.2% | 29.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -785.4% | 35.9% | ||
| Q2 24 | -504.3% | 41.5% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.03 | — | ||
| Q3 25 | $-0.19 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.17 | — | ||
| Q2 24 | $-0.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $458.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $396.4M |
| Total Assets | $1.4B | $4.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $458.4M | ||
| Q4 25 | $128.5M | — | ||
| Q3 25 | $83.2M | $336.0M | ||
| Q2 25 | $92.4M | $248.3M | ||
| Q1 25 | $159.3M | $282.3M | ||
| Q4 24 | $156.3M | — | ||
| Q3 24 | $126.6M | $181.0M | ||
| Q2 24 | $148.3M | $145.1M |
| Q1 26 | — | $396.4M | ||
| Q4 25 | $966.9M | — | ||
| Q3 25 | $964.0M | $385.5M | ||
| Q2 25 | $1.0B | $385.7M | ||
| Q1 25 | $1.0B | $380.5M | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | $298.6M | ||
| Q2 24 | $1.1B | $292.1M |
| Q1 26 | — | $4.5B | ||
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $4.0B | ||
| Q2 25 | $1.4B | $3.7B | ||
| Q1 25 | $1.3B | $3.6B | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | $3.3B | ||
| Q2 24 | $1.4B | $3.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $40.6M |
| Free Cash FlowOCF − Capex | $-44.6M | — |
| FCF MarginFCF / Revenue | -99.4% | — |
| Capex IntensityCapex / Revenue | 21.9% | — |
| Cash ConversionOCF / Net Profit | — | 5.03× |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.6M | ||
| Q4 25 | $-34.7M | — | ||
| Q3 25 | $-52.6M | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-11.6M | $-65.0M | ||
| Q4 24 | $-108.6M | — | ||
| Q3 24 | $-28.9M | — | ||
| Q2 24 | $-30.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-44.6M | — | ||
| Q3 25 | $-61.5M | — | ||
| Q2 25 | $-45.8M | — | ||
| Q1 25 | $-22.2M | — | ||
| Q4 24 | $-187.0M | — | ||
| Q3 24 | $-47.4M | — | ||
| Q2 24 | $-50.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | -99.4% | — | ||
| Q3 25 | -687.0% | — | ||
| Q2 25 | -267.9% | — | ||
| Q1 25 | -524.0% | — | ||
| Q4 24 | -3702.8% | — | ||
| Q3 24 | -728.4% | — | ||
| Q2 24 | -683.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 21.9% | — | ||
| Q3 25 | 99.7% | — | ||
| Q2 25 | 78.2% | — | ||
| Q1 25 | 251.1% | — | ||
| Q4 24 | 1552.7% | — | ||
| Q3 24 | 284.6% | — | ||
| Q2 24 | 274.6% | — |
| Q1 26 | — | 5.03× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -10.94× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
